We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.29B
AUM Growth
-$103M
Cap. Flow
+$25.6M
Cap. Flow %
0.78%
Top 10 Hldgs %
70.15%
Holding
85
New
9
Increased
10
Reduced
4
Closed
19

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$56.5M
2
ACET icon
Adicet Bio
ACET
+$55.5M
3
ZYME icon
Zymeworks
ZYME
+$53.2M
4
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$36.9M
5
DYN icon
Dyne Therapeutics
DYN
+$26.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.9M
2
GOSS icon
Gossamer Bio
GOSS
+$49.8M
3
RNAM
Avidity Biosciences
RNAM
+$47.3M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$39.1M
5
DSGN icon
Design Therapeutics
DSGN
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Miscellaneous 0.11%
3 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$504M
$698M 21.24%
11,584,280
– –
SRPT icon
2
Sarepta Therapeutics
SRPT
$2.38B
$389M 11.83%
2,999,453
– –
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$268M 8.16%
5,183,431
– –
ANAB icon
4
AnaptysBio
ANAB
$1.68B
$233M 7.09%
7,521,024
– –
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.87B
$166M 5.04%
3,730,730
+533,230
+17% +$22.4M
XNCR icon
6
Xencor
XNCR
$1.98B
$138M 4.19%
5,282,516
– –
ARVN icon
7
Arvinas
ARVN
$614M
$107M 3.25%
3,123,300
– –
RVMD icon
8
Revolution Medicines
RVMD
$45B
$106M 3.23%
4,458,731
+2,656,884
+147% +$56.5M
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$106M 3.22%
3,951,566
– –
ACAD icon
10
Acadia Pharmaceuticals
ACAD
$4.83B
$95.4M 2.9%
5,991,479
– –
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
$90M 2.74%
3,460,208
– –
KURA icon
12
Kura Oncology
KURA
$1.18B
$82.4M 2.51%
6,638,371
– –
ZLAB icon
13
Zai Lab
ZLAB
$2.94B
$66.2M 2.02%
2,157,686
+127,434
+6% +$4.02M
RLAY icon
14
Relay Therapeutics
RLAY
$4.17B
$62.2M 1.89%
4,163,824
– –
ZYME icon
15
Zymeworks
ZYME
$2.09B
$59.5M 1.81%
+7,568,573
New +$53.2M
ALEC icon
16
Alector
ALEC
$275M
$37.4M 1.14%
4,056,548
– –
NGM
17
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$32.3M 0.98%
6,435,518
+5,894,410
+1,089% +$36.9M
ACET icon
18
Adicet Bio
ACET
$89.8M
$31.8M 0.97%
+222,544
New +$55.5M
EWTX icon
19
Edgewise Therapeutics
EWTX
$4.68B
$31.2M 0.95%
3,493,194
– –
TNGX icon
20
Tango Therapeutics
TNGX
$3.8B
$30.5M 0.93%
4,201,414
– –
AVIR icon
21
Atea Pharmaceuticals
AVIR
$468M
$29.7M 0.91%
6,184,861
– –
VYGR icon
22
Voyager Therapeutics
VYGR
$216M
$29M 0.88%
4,753,907
– –
ALLO icon
23
Allogene Therapeutics
ALLO
$681M
$28.2M 0.86%
4,488,200
– –
DYN icon
24
Dyne Therapeutics
DYN
$4.53B
$26.9M 0.82%
+2,322,384
New +$26.9M
NUVB icon
25
Nuvation Bio
NUVB
$2.39B
$26.7M 0.81%
13,896,543
– –
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2022 Portfolio in Review

As of Q4 2022, EcoR1 Capital held 85 positions worth $3.29B, down 3% from $3.39B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

EcoR1 Capital's Q4 2022 filing shows 9 new, 10 increased, 4 reduced and 19 closed positions. Its largest new stake was Adicet Bio: 222,544 shares worth $31.8M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $70.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

  • EcoR1 Capital's largest Q4 2022 buy was Adicet Bio: 222,544 shares worth $31.8M.
  • EcoR1 Capital added most to Revolution Medicines in Q4 2022, an estimated $56.5M increase.
  • EcoR1 Capital's biggest Q4 2022 reduction was Design Therapeutics, cutting an estimated $22.1M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2022, selling an estimated $70.9M.
  • EcoR1 Capital's ten largest holdings make up 70% of its $3.29B portfolio in Q4 2022.
  • EcoR1 Capital opened 9 new positions and closed 19 in Q4 2022.
  • EcoR1 Capital's portfolio value fell 3% quarter-over-quarter to $3.29B.

Based on EcoR1 Capital's 13F filing for Q4 2022, filed 14 Feb 2023.